SCHEMBL19277486

SCHEMBL19277486

CCS(=O)(=O)c1cccc(CO)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSIP1 O75475 2/20 0.52
ENPP2 Q13822 1/20 0.46
IKBKB O14920 1/20 0.43
NPC1 O15118 1/20 0.41
TNF P01375 1/20 0.41
RAB9A P51151 1/20 0.41
NOD1 Q9Y239 1/20 0.41
BRD4 O60885 2/20 0.40
PTGES2 Q9H7Z7 1/20 0.40
S1PR1 P21453 4/20 0.40
NAMPT P43490 1/20 0.39
PRSS1 P07477 1/20 0.39
PRSS2 P07478 1/20 0.39
PRSS3 P35030 1/20 0.39
ADAMTS4 O75173 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTR6 P50406 2/20 0.39
GAA P10253 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31192532 1.00 PSIP1 (0.52) PSIP1ENPP2IKBKBNPC1TNF
SCHEMBL10066425 0.84 PSIP1 (0.56) PSIP1NPC1TNFRAB9ANOD1
SCHEMBL28266014 0.82 PSIP1 (0.54) PSIP1NPC1TNFRAB9ANOD1
SCHEMBL646928 0.82 ALDH1A1 (0.50) ENPP2IKBKBNPC1TNFRAB9A
SCHEMBL8032806 0.82 PTGES2 (0.42) ENPP2IKBKBPTGES2PRSS1PRSS2
SCHEMBL17048453 0.82 ADAMTS4 (0.41) ENPP2IKBKBNPC1TNFRAB9A
SCHEMBL17263850 0.81 PSIP1 (0.68) PSIP1NPC1RAB9ABRD4ALDH1A1
SCHEMBL23214313 0.81 PSIP1 (0.52) PSIP1NPC1TNFRAB9ANOD1
SCHEMBL2642741 0.81 PSIP1 (0.66) PSIP1ENPP2NPC1TNFRAB9A
SCHEMBL10180981 0.81 PSIP1 (0.52) PSIP1NPC1TNFRAB9ANOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692085-A2 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS Nxera Pharma UK Limited (GB) 2026-02-11 EP disclosed
EP-4041388-B1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-11-26 EP disclosed
US-12391641-B2 Prostaglandin EP4 receptor antagonist compounds Nxera Pharma UK Limitied (GB) 2025-08-19 US disclosed
US-20220411364-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS NXERA PHARMA UK LIMITED (GB) 2022-12-29 US disclosed
US-20220411364-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS NXERA PHARMA UK LIMITED (GB) 2022-12-29 US disclosed
EP-4041388-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS Heptares Therapeutics Limited (GB) 2022-08-17 EP disclosed
CN-114585603-A Prostaglandin EP4Receptor antagonist compounds 赫普泰雅治疗有限公司 2022-06-03 CN disclosed
WO-2021069927-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-15 WO disclosed
WO-2021069927-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-15 WO disclosed
US-20210040062-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2021-02-11 US disclosed
WO-2017141927-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND 大正製薬株式会社 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391641-B2 Prostaglandin EP4 receptor antagonist compounds PTGER1, PTGER4, PTGER2 PSIP1 1880/4885ENPP2 122/4885IKBKB 1016/4885
US-20210040062-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND CYP2F1, CYP21A2, CYP11B1 PSIP1 4326/4885ENPP2 2022/4885IKBKB 1082/4885
US-20220411364-A1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS PTGER1, PTGER4, PTGER2 PSIP1 1880/4885ENPP2 122/4885IKBKB 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.